Skip to main content Skip to search Skip to main navigation

ICH: Assembly Meeting 2025

The ICH Assembly met on 18–19 November 2025 in Singapore and welcomed NAFDAC (Nigeria) and SAHPRA (South Africa) as new members, along with two new observers. Elections were held for leadership roles across the Assembly, Management Committee, and MedDRA Steering Committee.

Several major guidelines reached Step 4, including:

  • M11 CeSHarP (harmonized electronic clinical protocol)
  • E2D(R1) on post-approval safety data reporting
  • M14 on RWD-based pharmacoepidemiology studies

Three important draft guidelines entered Step 2b public consultation:

  • E22 (Patient Preference Studies)
  • Q3E (Extractables & Leachables)
  • E20 (Adaptive Clinical Trial Designs)

MedDRA is now available in 27 languages, and the new LMS shows strong uptake. ICH also introduced a new training strategy, including the use of AI tools.

Five experts received the ICH Award 2025 for outstanding contributions. To mark 35 years of ICH, a new communication campaign and an official LinkedIn account were launched. The next Assembly meeting will take place in June 2026 in Rio de Janeiro.


Source:

ICH: Press release, ICH Assembly Meeting, Singapore, November 2025

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
What Types of Impurities may be Present in Active Substances?

What Types of Impurities may be Present in Active Substances?


Read more
There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

In pharmaceutical manufacturing, clean air is not a subjective perception but a precisely controlled technical condition that is essential for product safety. Heating, ventilation and air-conditioning (HVAC) systems ensure, through airflow management, air filtration and pressure control, that particles and microorganisms are kept away from critical areas. This is based on clearly defined requirements for air changes, cleanliness classes, airflow patterns and pressure concepts, all of which are designed according to the manufacturing process and contamination risk involved.
Read more
Previous
Next